Abpro Completes Business Combination with Atlantic Coastal Acquisition Corp. II
Abpro Corporation, a biotechnology firm dedicated to enhancing the lives of individuals facing severe diseases, has successfully completed its business combination with Atlantic Coastal Acquisition Corp. II. This marks a significant milestone for the company, which will now operate under the name Abpro Holdings, Inc., with Abpro Corporation as its wholly-owned subsidiary.
Trade Readiness and Ticker Symbols
Following the completion of this business combination, Abpro Holdings is slated to begin trading on The Nasdaq Global Market under the ticker symbol "ABP". Additionally, its warrants will trade on The Nasdaq Capital Market under the ticker "ABPWW", signaling to investors an exciting new chapter for the company.
Innovative Antibody Therapies in Development
Abpro is currently advancing its pioneering next-generation antibody therapies, with a focus on treatments for HER2+ cancers. This initiative includes targeting breast, gastric, and colorectal cancers, in addition to addressing conditions such as Wet AMD/DME and COVID-19. Utilizing the proprietary DiversImmune® platform, Abpro is well-positioned to make significant advancements in therapeutic treatments.
Notable Partnerships
A noteworthy partnership for Abpro is its collaboration with Celltrion, a prominent South Korean pharmaceutical leader. Together, they are working on ABP 102, a T-cell engager which is particularly aimed at treating HER2+ breast, gastric, and pancreatic cancers. This collaboration embodies Abpro's commitment to tackling complex medical challenges through innovation and partnerships.
Financial Advisor and Legal Counsel Involvement
Brookline Capital Markets, part of Arcadia Securities, acted as the financial advisor to Abpro Corporation, providing valuable guidance throughout the business combination process. Meanwhile, Pillsbury Winthrop Shaw Pittman LLP served as legal counsel for Atlantic Coastal, ensuring that all regulatory requirements were thoroughly addressed. For Abpro, Nelson Mullins Riley & Scarborough LLP undertook the legal counsel responsibilities, contributing to a seamless transition into their new corporate structure.
About Abpro Corporation
Abpro is a cutting-edge biotechnology company based in Woburn, Massachusetts, focusing on the development of next-generation antibody therapies. With a mission to improve the lives of people grappling with severe and life-threatening illnesses, Abpro stands at the forefront of medical innovation. Its commitment to harnessing the potential of advanced biotherapeutics positions the company as a leader in the industry. For further details, individuals can explore abpro.com.
Contact Information
Abpro remains keen on investor relations and engagement. Interested parties are encouraged to connect through the designated communications channels for inquiries and further information regarding Abpro's trajectory and ongoing advancements.
Frequently Asked Questions
What is Abpro Corporation's primary focus?
Abpro Corporation specializes in developing next-generation antibody therapies for severe diseases, including various cancers and COVID-19.
What are the ticker symbols for Abpro Holdings?
Abpro Holdings will trade under the ticker symbol "ABP", while its warrants will be listed as "ABPWW" on The Nasdaq markets.
Who are Abpro's key partners?
One of Abpro's significant partnerships is with Celltrion, which aids in the development of innovative cancer treatment therapeutics.
Where is Abpro based?
Abpro is headquartered in Woburn, Massachusetts, where it focuses on biotechnology research and development.
Who acted as financial advisors during the business combination?
Brookline Capital Markets served as the financial advisor to Abpro Corporation during its business combination with Atlantic Coastal Acquisition Corp. II.
